SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma, a rare hematologic disease (CARAMBA)
Senior Researcher | Principal Investigator Adoptive Cellular Therapy Research Group
Adoptive Cell Therapy. Hemato-oncology
CARAMBA will be the first clinical trial targeting the myeloma-specific protein SLAMF7. The project's mission is to better understand the role of CAR-T therapy in myeloma and to explore sustainable regulatory and funding approaches so that healthcare systems can ensure patient access to this type of innovation.
- Convocation: 2018-2022
- Reference: 754658
- Start date: January 1, 2018
- End date: April 30, 2022
- Funder: Comisión Europea
- Grant: € 6 097 875
- Nature of project: International
- Award year 2017
Need more information?
If you are interested in learning more about our research, please contact us